Literature DB >> 15824503

The ethics of gene therapy and abortion: public opinion.

M D R Evans1, Jonathan Kelley, Esmail D Zanjani.   

Abstract

On the grounds that the public should be consulted in decisions concerning the legitimate scope of germ-line genetic therapy (GLGT), survey data on the ethics of GLGT were collected from a large (n = 1,403) representative national sample of Australians in 2002. The data show that opinion is quite divided over GLGT in the case of a 'death sentence' genetic defect: 36% would forbid it, 23% have mixed feelings and 41% would allow it. For less serious conditions there is more opposition to GLGT. Thus, 48% would forbid GLGT to remedy a minor physical defect and 52% would oppose GLGT to counteract a propensity to violence, but fully 73% would disallow GLGT for cosmetic reasons. The data also show that opposition to abortion is lower than opposition to GLGT in the case of a 'death sentence' genetic defect, but at about the same level as, or greater than, opposition to GLGT for less serious issues. The questions show good measurement properties, including low missing data rates, so they are likely to provide an accurate picture of the public's views on the ethics of GLGT. It is suggested that a system for monitoring public opinion on these issues be developed. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Year:  2005        PMID: 15824503     DOI: 10.1159/000083910

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  2 in total

1.  US attitudes toward human embryonic stem cell research.

Authors:  M D R Evans; Jonathan Kelley
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

2.  Reasons for being in favour of or against genome modification: a survey of the Dutch general public.

Authors:  S Hendriks; N A A Giesbertz; A L Bredenoord; S Repping
Journal:  Hum Reprod Open       Date:  2018-05-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.